Isomorphic Labs Completes $5 Billion Series C Funding Round to Advance AI Drug Discovery Infrastructure
English text is being prepared.
Isomorphic Labs announced on November 17 that it had completed a $5 billion Series C funding round, which will be used to advance foundational simulation models, expand its pipeline of drug candidates, and build AI-driven bioengineering infrastructure. A 2024 BCG report said that AI-generated drug molecules have an 80%-90% success rate in Phase I clinical trials, compared with the historical industry average of 40%-65%. Soochow Securities believes that the AI drug discovery technology stack is shifting from standalone algorithmic tools to a multimodal technology matrix.
Why read this
AI score 60
Drawing on Isomorphic Labs' financing plans and BCG clinical data, the report outlines how AI drug discovery is expanding from algorithmic tools into a multimodal technology matrix.
Topics
Body
AI助推新药研发成功率显著提升,AI制药价值链持续拓展财联社下载客户端 独家抢先看2026年11月19日 08:05:00 来自北京Updated 2026年11月19日 08:20:23
AI制药公司IsomorphicLabs11月17日宣布完成50亿美元C轮融资。IsomorphicLabs计划利用这笔资金继续推进基础模拟模型的发展,扩大内部及合作药物候选项目的规模,并建设全球AI驱动的生物工程基础设施。
东吴证券表示,据BCG2024年报告,AI生成的药物分子在I期临床试验中成功率达到80%-90%,远高于40%-65%的历史行业平均水平。AI有望助推新药研发整体成功率显著提升。AI制药技术栈完成了从单一算法工具到多模态技术矩阵的根本性重构。
据财联社主题库显示,相关上市公司中:
义翘神州生产和销售的现货产品种类合计超过74,000种,包括超9,000种重组蛋白、14,000余种抗体、超5万种基因及性能优越的无血清培养基系列产品,能够覆盖生命科学研究的多个领域。
“特别声明:以上作品内容(包括在内的视频、图片或音频)为凤凰网旗下自媒体平台“大风号”用户上传并发布,本平台仅提供信息存储空间服务。
Notice: The content above (including the videos, pictures and audios if any) is uploaded and posted by the user of Dafeng Hao, which is a social media platform and merely provides information storage space services.”
AI Trends